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Abstract: Mesenchymal stem cells have an important potential in the treatment of age-related diseases.
In the last years, small extracellular vesicles derived from these stem cells have been proposed as
cell-free therapies. Cellular senescence and proinflammatory activation are involved in the loss of
therapeutic capacity and in the phenomenon called inflamm-aging. The regulators of these two
biological processes in mesenchymal stem cells are not well-known. In this study, we found that p65
is activated during cellular senescence and inflammatory activation in human umbilical cord-derived
mesenchymal stem cell. To demonstrate the central role of p65 in these two processes, we used small-
molecular inhibitors of p65, such as JSH-23, MG-132 and curcumin. We found that the inhibition
of p65 prevents the cellular senescence phenotype in human umbilical cord-derived mesenchymal
stem cells. Besides, p65 inhibition produced the inactivation of proinflammatory molecules as
components of a senescence-associated secretory phenotype (SASP) (interleukin-6 and interleukin-8
(IL-6 and IL-8)). Additionally, we found that the inhibition of p65 prevents the transmission of
paracrine senescence between mesenchymal stem cells and the proinflammatory message through
small extracellular vesicles. Our work highlights the important role of p65 and its inhibition to restore
the loss of functionality of small extracellular vesicles from senescent mesenchymal stem cells and
their inflamm-aging signature.
Keywords: mesenchymal stem cells; inflamm-aging; cellular senescence; SASP; sEV
1. Introduction
Mesenchymal stem cells (MSCs) are stromal stem cells from adult tissues, such as
bone marrow, adipose tissue, the umbilical cord and others [1]. They have a high potential
to be used as treatments for age-related diseases, because they are multipotent and can
differentiate cell types from the mesoderm lineage [2]. The cells can easily expand in vitro,
but aging affects the self-renewal capacity of MSCs [3,4]. During the aging, there are two
important processes (cellular senescence and proinflammatory activation) involved in the
loss of promising characteristics of MSCs in cell-based therapy [5]. Cellular senescence
and proinflammatory activation (PA) produce a persistent low-grade systemic status
called inflamm-aging that is associated with the degeneration of organs and tissues. The
consequence of this biological process is the development of age-related diseases [6].
During the aging process, there exists an accumulation of senescent cells associated
with the developing of age-related diseases [7]. Cellular senescence is a process charac-
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terized by the loss proliferation capacity and elevated lysosomal activity detected by the
β-galactosidase (β-gal) activity [8]. Besides, senescent cells produce and deliver cytokines,
chemokines, lipid mediators, metabolites and small extracellular vesicles (sEV) called
senescence-associated secretory phenotypes (SASP) [9]. The conditioned medium from
senescent cells can induce senescence in neighboring cells by way of the paracrines [10].
Extracellular vesicles (EV) are biological, cellular particles that are contained in bodily flu-
ids [11]. In the last years, our group has reported that sEV are involved in the transmission
of the senescence message by regulation of the inflammatory pathways (Toll-like receptor
type 4 [4], mTOR [12] and interferon pathways [10]). Besides, the modification of miRNAs
or proteins contained in EV can be used as antiaging therapy [12–14]. For example, sEV can
ameliorate the mTOR pathway involved in the aging of MSCs [12] and have an important
therapy in neurogenerative [15] and cardiovascular diseases [16].
The NF-kB family is integrated by five transcription factors (p50, p52, p65, c-REL
and ReIB) implicated in immune and inflammatory responses [17]. The NF-kB path-
way can be activated by many stimuli (cytokines, oncogenes, oxidative stress and DNA
damage) [18,19]. The ReIA/p65 complex is involved in the canonical pathways NF-kB
is involved in: (1) the maintained cellular senescence in mouse embryonic fibroblasts
(MEFs) [20], (2) the proinflammatory activation by tumor necrosis factor α (TNF-α) in
human MSCs [21] and (3) the activation of immune cells during aging [22,23]. We pro-
posed to study the role of the p65 pathway in the cellular senescence and proinflammatory
activation of MSCs and their intercellular communication by sEV using small inhibitors
(JSH-23, MG-132 and curcumin).
2. Results
2.1. p65 Is Involved in the Cellular Senescence Establishment and Proinflammatory Activation
in MSCs
In order to study the p65 pathway in inflamm-aging, we selected MSCs from the
umbilical stroma cord (UC-MSCs) characterized by the evaluation of mesenchymal and
haematopoietic markers using flow cytometry. The MSCs were positive for mesoderm
markers (CD90, CD73 and CD105), and the percentage of positive cells was less than 1%
for the hematopietic markers (CD34 and CD45) (Figure 1). Additionally, we evaluated
the undifferentiated markers (Nanog, Sox2, Oct3/4 and Rex1) at the RNA level in MSCs in
comparison to healthy chondrocytes (TC28a2). The MSCs showed a high-level expression
of markers for the cell undifferentiated state compared to healthy chondrocytes (Figure 1).
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Figure 1. Characterization of m senchymal stem cells (MSCs). Workflow of the isolation of MSCs
from the stroma u bilic l t r of the % of posit ve cells for the mes nchymal markers
(CD90, CD73 and CD105) and hematopoietic markers (CD34 and CD45) using FACS (bottom left).
Levels of markers for the cell undifferentiated state (Nanog, Oct3/4, Sox2 and Rex1) at mRNA by
qPCR-RT (bottom right) in MSCs and healthy chondrocytes (TC28a2).
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Firstly, we established two cellular senescence models in MSCs: (i) DNA damage-
induced senescence (DDIS): MSCs were treated with etoposide for two days. Then, the
cells were withdrawn from the etoposide for four days, allowing the cellular senescence
phenotype (Figure 2A) and (ii) therapy-induced senescence (TIS): MSCs were treated
for six days with palbociclib, a selective inhibitor of cyclin-dependent kinase 4 and 6
(CDK4/6) used to induce cell cycle arrest and the cellular senescence phenotype in cancer
cells [24] (Figure 2A). The endogenous expression of p65 was monitored by quantitative
reverse-transcription PCR (qPCR-RT). We obtained a statistically significant increase in
the transcription of p65 in the senescent MSCs (Se(DDIS) and Se(TIS)) in comparison
to proliferantive or nonsenescent (Non-Se) MSCS (Figure 3A,B). Besides, we observed a
statistically significant high content of proinflammatory-elemented SASP regulated by
the NF-kB pathway (interleukin-6 and interleukin-8 (IL-6 and IL-8)), using ELISA in the
conditioned medium from Se (DDIS and TIS) (Figure 3D,E).
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Figure 2. Schematic representation of (A) two cellular senescence models in MSCs: DNA damage-
induced senescence (DDIS) (up) and therapy-induced senescence (TIS) (bottom) and (B) the proin-
flammatory activation (PA) model in mesenchymal stem cells (MSCs) using tumor necrosis factor
α (TNF-α).
In parallel, we performed an inflammatory model in MSCs using tumor necrosis factor
alpha (TNF-α) involved in the proinflammatory activation (PA) of MSCs after treatment for
six days (Figure 2B). We evaluated the expression of p65 at the RNA level and the proin-
flammatory components (IL-6 and IL-8) by qPCR-RT and ELISA, respectively. We found
that the MSCs treated with TNF-α showed statistically significant high mRNA levels of p65
(Figure 3C) and high levels of IL-6 and IL-8 in their conditioned medium (Figure 3D,E).
With these data, we confirmed that in the cellular senescence and proinflammatory
activation of MSCs exists an activation of the p65 pathway.
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Figure 3. Evaluation of the p65 pathway in cellular senescence and proinflammatory activation; qPCR
to determine the mRNA p65 expression in (A) DNA damage-induced senescence (DDIS), (B) therapy-
induced senescence (TIS) and (C) proinflammatory activation (PA) in mesenchymal stem cells (MSCs).
Data represent the mean ± SD of three independent experiments. Nonparametric Kolmogorov–
Smirnov test was used to calculate the significance, and it was represented as
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2.2. Inhibition of p65 Prevents the Cellular Senescence Establishment and Proinflammatory
Activation in MSC
To assess the relevance of p65 in the cellular senescence and proinflammatory activation
of MSCs, we selected a inhibitor of the p65 pathway (JSH-23, MG-132 or curcumin) [25–27] to
affect the cellular senescence and roinflammatory activation. In DDIS, after removing the
eto oside for one day, cells wer treated with the in ibitors of the p65 p thway for three d ys
(Figure 4A). In the DDIS, TIS and PA models, cel s were treated with the inhibitors after three
days of treatment with palbociclib and TNF-α, respectively (Figure 4A,B).
Then, we valuated in the DDIS, TIS a d PA the proliferatio apacity of the cells using
cryst l violet staining and its quantification (Figure 5A,B). The Se (DDIS and TIS) and TNF-
α showed a statistiscally significant decrease of the proliferation capacity in comparison
to Non-Se (DDIS and TIS) and DMSO, respectively (Figure 5A,B). Besides, we found that
treatment with the inhibitors of the p65 pathway (JSH-23, MG-132 and curcumin) prevents
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statistically significant cell cycle arrest in DDIS, TIS and PA (Figure 5A,B). Additionally, we
evaluated the lysosomal activity by measuring β-gal in the senescence process in MSCs.
The levels of β-gal increased statistically significantly in Se (DDIS and TIS) and decreased
when the cells were treated with JSH-23, MG-132 or curcumin (Figure 5C). Altogether, these
data suggest that p65 is an important pathway in the establishment of cellular senescence
and proinflammatory activation on MSCs.
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Figure 5. The inhibition of the p65 pathway prevents the induction of cellular senescence and
proinflammatory activation. Quantification and representative images of crystal violet to evaluate
the proliferation capacity in (A) mesenchymal stem cells (MSCs) treated with JSH-23, MG-132 and
curcumin during the cellular senescence establishment (DNA damage-induced senescence ( DIS)
and therapy-induced senescence (TIS)) and (B) MSCs treated with JSH-23, MG-132 and curcumin
during the proinflammatory activation (PA). All data represent the mean ± SD of three independent
experiments. Nonparametric Kolmogorov–Smirnov test was used to calculate the significance, and
it was represented as
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β-galactosidase activity in MSCs treated with the pharmacological inhibition of the p65 pathway
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NON-Se: Proliferative or nonsenescent MSCs, Se: Senesc nt MSCs; TNF-α: M Cs treat d with tumor
necrosis factor alpha, JSH-23: Senescent (DDIS and TIS) or proinflammatory-activated (TNF-α) MSCs
treated with JSH-23, MG-132: Senescent (DDIS and TIS) or proinflammatory activated (TNF-α) MSCs
treated with MG-132, Curc.: Senescent (DDIS and TIS) or proinflammatory activated (TNF-α) MSCs
treated with curcumin and A.U: arbitrary units.
2.3. p65 Pathway Modulate the Production of sEV in Senescent and Pro-Inflammatory-Activated
MSCs
In order to determine if the p65 pathway is involved in the release of EV in inflamm-
aging, we treated the cells with the drugs to induce cellular senescence (DDIS and TIS)
and proinflammatory activation, as previously described, followed by treatment with the
inhibitors of the p65 pathway for 72 h. The cells were then washed with PBS to remove the
inhibitors, and the sEV were collected three days later (Figure 6A,B).
The size of the EV diameter and number of EVs were measured using a nanoparticle
tracking analysis (NTA). We observed that the size of the EV diameter was around 150 nm,
as in the exosome-like particles of sEV, and the diameter size of the EV was not statistically
significant from the Se (DDIS and TIS) and TNF-α-treated MSCs, compared to those
treated with JSH-23, MG-132 and curcumin in the different models (Figure 7A,B). With
respect to EV number, we found that Se- (DDIS and TIS) and TNF-α-treated MSCs released
Int. J. Mol. Sci. 2021, 22, 3367 7 of 17
statistically significantly increased the number of particles compared to Non-Se- and
DMSO-treated MSCs, respectively. Besides, treatments with JSH-23, MG132 and curcumin
separately prevented a partial release in cellular senescence and proinflammatory activation
(Figure 7C,D). These data show that the pharmacological inhibition of the p65 pathway
prevents the release of EV from senescent and proinflammatory MSCs.
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pathway in the release of small extracellular vesicles (sEV). sEV were isolated from (A) cellular
senescence models (DNA damage-induced senescence (DDIS) and therapy-induced senescence (TIS))
and (B) proinflammatory activation (PA) in mesenchymal stem cells (MSCs) after the treatment with
pharmacological inhibitors (JSH-23, MG-132 and curcumin) during the induction.
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Quantification of the number of particles in (C) MSCs treated with JSH-23, MG-132 and curcumin
during the cellular senescence induction (DDIS and TIS) and (D) PA using an NTA. The graphs
shown the mean ± SD of three independent experiments. Nonparametric Kolmogorov–Smirnov
test was used to calculate the significance, and it was represented as
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NON-Se: proliferative or nonsenescent MSCs, Se: senescent MSCs, TNF-α: MSCs treated with tumor
necrosis factor alpha, JSH-23: senescent (DDIS and TIS) or proinflammatory-activated (TNF-α) MSCs
treated with JSH-23, MG-132: senescent ( IS and TIS) or proinflammatory-activated (TNF-α) MSCs
treated with MG-132, Curc.: senescent (DDIS and TIS) or proinflammatory-activated (TNF-α) MSCs
treated with curcumin, nm: nanometer and M:1000.
2.4. p65 Is a Common Pathway Involved in the Cellular Senescence and Proinflammatory
Activation Paracrine through sEV
To further determine the implication of the p65 pathway in the paracrine transmission
of inflamm-aging, we isolated EV from senescent and proinflammatory MSCs. The recipient
proliferative MSCs (Non-Se or MSCs) were treated with sEV from Se (DDIS and TIS) and
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TNF-α and simultaneously with the pharmacological inhibitors of the p65 pathway (JSH-23,
MG-132 and curcumin) for six days (Figure 8A,B).
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Figure 8. Schematic representation of the details of the experimental settings to the p65 pathway
involved in the cellular senescence and proinflammatory paracrine transmission by small extracellular
vesicles (sEV). (A) Proliferative mesenchymal stem cells (MSCs) (Non-Se) were treated with sEV
from Se (DNA damage-induced senescence (DDIS) and therapy-induced senescence (TIS)) and the
small inhibitors (JSH-23, MG-132 and curcumin) for six days. (B) MSCs were treated with sEV from
proinflammatory-activated MSCs (tumor necrosis factor alpha (TNF-α)) and JSH-23, MG-132 and
curcumin for six days.
The sEV from Se (DDIS and TIS) and TNF-α induced a statistically significant cell
cycle arrest measured by the bromide 3-(4,5-dimetiltiazol-2-il)-2,5-diphenyltetrazolium
(MTT) assay in comparison with the recipient cells treated with sEV from Non-Se- and
DMSO-treated MSCs (Figure 9A,B). The recipient MSCs treated with JSH-23, MG-132
and curcumin prevented the loss of prolif ration by sEV f om DDIS, TI and TNF-α
(Fig re 9A,B). Besi es, the pharmacological inhibitor of p65 statistically re uced the
significantly high levels of senescence-associated β-gal activity in the paracrine senescence
transmission by sEV, as shown in Figure 9C. Altogether, these data suggest that the p65
pathway is involved in the transmission of senescence and proinflammatory activation
paracrine through sEV.
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Figure 9. Pharmacological inhibition of the p65 pathway prevents the cellular senescence and
proinflammatory paracrine transmission by small extracellular vesicles (sEV) in mesenchymal stem
cells (MSCs). Quantification of the proliferation capacity using the MTT (bromide 3-(4,5-dimetiltiazol-
2-il)-2,5-diphenyltetrazolium) assay in (A) recipient proliferative MSCs (Non-Se) treated with sEV
from Non-Se, Senescent MSCs (DDIS and TIS) and JSH-23 (sEV-DDIS-JSH-23 and sEV-TIS-JSH-23),
MG-132 (sEV-DDIS-MG-132 and sEV-TIS-MG-132) and curcumin (sEV-DDIS-Curcumin and sEV-
TIS-Curcumin) and (B) recipient MSCs treated with sEV from DMSO (without TNF-α treatment);
TNF-α (tumor necrosis factor alpha treatment) and inhibitor of the p65 pathway (JSH-23, MG-132
and curcumin) (sEV- TNFα-JSH-23, sEV- TNFα-MG-132 and sEV- TNFα-Curc). (C) Quantification of
senescence-associated β-galactosidase activity in recipient Non-Se treated with sEV from Non-Se,
Senescent MSCs (DDIS, and TIS) and JSH-23 (sEV-DDIS-JSH-23 and sEV-TIS-JSH-23), MG-132 (sEV-
DDIS-MG-132 and sEV-TIS-MG-132) and curcumin (sEV-DDIS-Curcumin and sEV-TIS-Curcumin).
The graphs show the mean ± SD of three independent experiments. Nonparametric Kolmogorov–
Smirnov test was used to calculate the significance, and it was represented as
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3. Discussion
Inflamm-aging is a process characterized by the persistent low-grade systemic proin-
flammatory status producing tissue damage in aging [6]. The senescent and proinflamma-
tory activation of MSCs delivered proinflammatory components, such as IL-6 and IL-8, that
positively stimulate inflamm-aging in the body [5]. The process affects the proliferation
and self-renewal of MSCs to be used as a therapy in age-related diseases [3,5]. Due to that,
we proposed to study the cellular senescence and proinflammatory activation [5] in human
MSCs using DDIS, TIS and PA to mimic the physiological status at the in vitro level.
The canonical NF-kB (p65) pathway is activated in senescent cells and functions as a
key SASP regulator through p53 and the production of proinflammatory cytokines and
chemokines in several types of cells [20,28]. This pathway is involved in the proinflamma-
tory activation of TNF-α in MSCs [21,29]. For this reason, we selected pharmacological
inhibitors of the p65 pathway: (i) JSH-23, a well-known selective inhibitor of nuclear translo-
cation of p65 [25], (ii) MG-132, which blocks activation of p65 by preventing degradation
of IkB [27] and (iii) curcumin, a naturally derived compound reported to be an effective
nuclear p65 inhibitor [26,30]. Firstly, we validated that the induction of cellular senescence
(DDIS and TIS) and proinflammatory activation in human MSCs are regulated by the p65
pathway, based on cell proliferation and β-gal activity. Our results confirmed Pandey’s
results, which reported that expression of the p65 pathway components is increased in
aged MSCs from adipose tissue and bone marrow [31] and inflammation-induced TNF-α
in MSC-derived bone marrow [29] (Figure 3).
The SASP is the main source of senescent cell communication and microenviron-
ment in the development of age-related diseases. During the last decade, many studies
have focused on the therapeutic potential of pharmacological inhibitors of SASP (called
senomorphic drugs), like the p65 pathway [32], to disrupt paracrine transmission cellular
senescence. Our results coincide with results from Chien et al. in human fibroblasts [33]
(Figures 5 and 7). The use of sEV-based therapy from MSCs has a high potential for treating
age-related diseases [9], because the sEV cargo is from various cell compartments that
mediate intracellular communication via shuttling bioactive signaling molecules or by the
direct activation of signaling pathways to recipient cells [11]. For example, the EV from
MSCs have immunomodulation effects in immune cells in the lungs in models of asthma,
a chronic inflammatory lung disease [34], and bovine milk sEV can ameliorate chronic
inflammatory disorders (arthritis and allergy) [35,36].
However, the mechanism that can affect the therapeutic potential is not clear. In the
last years, it has been identified that sEV can mediate paracrine senescence in different
contexts using human fibroblasts [10] and bone marrow MSCs [12]. We confirmed that the
transmission of paracrine senescence (DDIS and TIS) by sEV in human MSCs can occur,
and we discovered that sEV from proinflammatory-activated MSCs can induce cell cycle
arrest in normal MSCs (Figures 9 and 10). Both processes are regulated by the p65 pathway
in MSCs, which we showed in the functionality experiment with the inhibitors.
The pharmacological inhibitors of the p65 pathway (JSH-23, MG-132 and curcumin)
have high potential to use comparable senomorphic drugs to show a decrease in the release
of sEV in senescent- and proinflammatory-activated MSCs (Figure 7). With our results,
these inhibitors could prevent cellular senescence and inflammation in MSCs characterized
by inflamm-aging. The inhibitors of the p65 pathway could be used as senomorphic
drugs to inhibit the inflamm-aging effect in MSCs (Figure 10) and maintain the stem
cell properties of MSCs in in vitro cultures to use as therapy in age-related diseases like
atherosclerosis [37]. The study of cargo sEV (protein, lipids and RNAs) involved in a
therapy capacity regulated by the inhibition of the p65 pathway could be a promising point
to advance the knowledge of sEV-based therapy, because the p65 pathway is related with
age-related diseases like osteoarthritis [38].
A limitation of the current study is the performance of only in vitro studies and
the short time studied. Longer studies will need to be performed and validated in
in vivo models. However, this study is a proof-of-concept to use the pharmacological
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inhibitors of p65 (JSH-23, MG-132 and curcumin) to maintain the properties of MSCs
and their sEV throughout their aging. Besides, they can decrease the accumulation of
senescent- and proinflammatory-activated MSCs in the body to delay the development of
age-related diseases.
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4. Materials and Methods
4.1. Cell Culture
Hu an mbilical cords (UC) were obtained from caesarean sections p rformed on
healthy women at the Maternity Facility at C mplejo Hospitalario Universitario A Coruña
(CHUAC). All tissues were obtained with fully i formed consent and ethical approval
by the supervisor of the Ethical Committee (CEIC: 2019/026) of Galicia. All the women
were between 26–35 years of age. Mesenchymal stem cells (MSCs) were isolated from
UC using the protocol developed by Arufe’s group [1]. Briefly, the tissue was washed
with phosphate-buffered saline and cut into small pieces (explants). These explants were
then incubated for three five-minute periods in an enzyme mixture containing 1.2-U/mL
dispase and 112-U/mL type I collagenase (all from Sigma-Aldrich, Madrid, Spain) and
cultured in Dulbecco′s Modified Eagle’s Medium with 10% (v/v) fetal bovine serum, 1%
(v/v) penicillin and 1% (v/v) streptomycin (all from Sigma-Aldrich, Madrid, Spain) and
growth adhered to the plastic plate. After three days, the explants were removed from the
plate, leaving the attached UC-MSCs, which were then cultured in a monolayer in the same
medium. When the cells were in passage 4 and 90% confluent, they were removed from
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the plate using 2% (v/v) trypsin (Sigma-Aldrich, Madrid, Spain) in phosphate-buffered
saline to seed in the plates to perform the experiments. T/C-28a2 (TC28a2) immortalized
healthy chondrocytes from human costal cartilage from a 15-year-old female (SCC042)
(Sigma-Aldrich, Madrid, Spain) were cultured in Dulbecco′s Modified Eagle’s Medium
with 10% (v/v) fetal bovine serum, 1% (v/v) penicillin and 1% (v/v) streptomycin (all from
Sigma-Aldrich, Madrid, Spain).
4.2. Cellular Senescence Induction in UC-MSCs
Cellular senescence was induced in proliferative UC-MSCs using two models: (1)
DDIS: the UC-MSCs were cultured with DMEM supplemented with 10% (v/v) FBS, 1%
(v/v) penicillin, 1% (v/v) streptomycin (all from Sigma-Aldrich, Madrid, Spain) and 1-µM
Etoposide (MedChemexpress, New Jersey, USA) (Table A1) for two days. The cells were
then washed with PBS and cultured with DMEM supplemented with 10% (v/v) FBS, 1%
(v/v) penicillin and 1% (v/v) streptomycin (all from Sigma-Aldrich, Madrid, Spain) for four
days (Figure 2A). (2) TIS: the UC-MSCs were cultured with DMEM supplemented with
10% (v/v) FBS, 1% (v/v) penicillin, 1% (v/v) streptomycin (all from Sigma-Aldrich, Madrid,
Spain) and 1-µM Palbociclib (CDK4/6 inhibitor) (MedChemexpress, New Jersey NJ, USA)
(Table A1) for three days. After that, the cells were washed with PBS and cultured with
DMEM supplemented with 10% (v/v) FBS, 1% (v/v) penicillin and 1% (v/v) streptomycin
(all from Sigma-Aldrich, Madrid, Spain) for three days. The cells were then washed with
PBS and cultured with DMEM supplemented with 10% (v/v) FBS, 1% (v/v) penicillin and
1% (v/v) streptomycin (all from Sigma-Aldrich, Madrid, Spain) for three days (Figure 2A).
4.3. Pro-Inflammatory Activation in UC-MSCs
UC-MSCs were incubated with 5-ng/mL TNF-α recombinant (Immunotools, Gladi-
olenweg, Germany) in DMEM supplemented with 10% (v/v) FBS, 1% (v/v) penicillin and
1% (v/v) streptomycin for three days. After that, the cells were washed with PBS and were
cultured with DMEM supplemented with 10% (v/v) FBS, 1% (v/v) penicillin and 1% (v/v)
streptomycin (all from Sigma-Aldrich, Madrid, Spain) for three days (Figure 2B).
4.4. Treatment with Drugs
MSCs were seeded at a 50% confluence. The next day, the induction of senescence and
inflammatory activation was started, as previously described. Three days later, the cells
were treated with drugs at suitable concentrations (Table A1) for six days.
4.5. Treatment with sEV
The proliferative UC-MSCs were plated. One day later, the cells were treated with
sEV from donor cells for six days with the same number of sEV in DMEM 10% (v/v) FBS-
depleted sEV and 1% (v/v) penicillin and 1% (v/v) streptomycin (all from Sigma-Aldrich,
Madrid, Spain).
4.6. Cell Proliferation Assay
The number of cells was evaluated by the colorimetric MTT assay (Cell Proliferation
Kit I, Roche, Basel, Switzerland) according to manufacturer’s instructions. The absorbance
was measured with a NanoQuant microplate reader (Tecan Trading AG, Männedorf,
Switzerland) at 540 nm.
4.7. Crystal Violet Staining
The plates were fixed using 4% (v/v) paraformaldehyde for 15 min at room temperature
and washed three times with PBS. Then, the plates were stained with 0.5% (v/v) crystal violet
solution and scanned. The quantification of crystal violet was performed by solubilizing
crystal violet staining (Sigma-Aldrich, Madrid, Spain) with 30% (v/v) acetic acid and
measuring the absorbance at 570 nm using a NanoQuant microplate reader (Tecan Trading
AG, Switzerland).
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4.8. β-GALACTOSIDASE Assay
β-gal activity was measured using the Thermo Scientific Mammalian β-Galactosidase
Assay Kit (Thermo Fisher, Foster City, CA, USA), following the manufacturer’s instructions,
at 405 nm using a NanoQuant microplate reader (Tecan Trading AG, Switzerland).
4.9. Isolation Extracellular Vesicles
The cells were cultured with DMEM supplemented with 10% (v/v) sEV-depleted FBS
and 1% (v/v) penicillin and 1% (v/v) streptomycin (all from Life Technologies, Carlsbad,
CA, USA). Cells were cultured to 80% confluence, and the supernatants were collected
after 72 h. Supernatants were centrifuged at 2000× g for 10 min at 4 ◦C and filtered using
a sterile 0.22-µm filter (GE Healthcare Life Sciences, Little Chalfont, UK) to eliminate
debris, and they were transferred into new ultracentrifugation tubes (Beckman Coulter,
Mississauga, ON, Canada) and centrifuged at 100,000× g for 2 h at 4 ◦C in an Optimal-
90K ultracentrifuge with a 60 Ti rotor (Beckman Coulter, Mississauga, ON, Canada). The
last supernatants containing exosome-depleted FBS were removed, and the pellets were
resuspended in 200-µL PBS (MP Biomedicals, Illkrich-Graffenstaden, France).
4.10. RNA Isolation, Synthesis cDNA and qPCR-RT
Total RNA was extracted using TRIzol Reagent (Thermo Fisher, Foster City CA, USA)
according to the manufacturer’s instructions. cDNA synthesis was performed using a
High-Capacity cDNA Reverse Transcriptase kit (Thermo Fisher, Foster City, CA, USA).
qPCR reactions were performed using SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA, USA) and the primers in the Table A3 using LightCycler 480 (Roche,
Basel, Switzerland).
4.11. Flow Cytometry
UC-MSCs were washed twice in PBS and pre-blocked with 2% (v/v) rat serum in PBS.
The cells were incubated with the primary antibody at suitable concentrations (Table A2)
for 1 h at room temperature. After incubation, the cells were washed twice with PBS. The
FACS data was generated by BD FACSDiva software (BD Science, San Jose, CA, USA).
Negative control staining was performed using the isotype (Table A2).
4.12. ELISA
The supernatant from UC-MSCs were diluted 1:2 prior to analysis. Human IL-6
and IL-8 immunoassays (h-IL6-EIA-1 and h-IL8-EIA-5, respectively, Mab Tag GmbH)
were performed following the manufacturer’s instructions. The absorbance from the
samples was measured at 540 nm using a NanoQuant microplate reader (Tecan Trading
AG, Switzerland).
4.13. Nanoparticle Tracking Analysis
The Brownian motion of the particles in a NanoSight LM12 using Nanoparticle Track-
ing Analysis 2.3 software (NanoSight Ltd., Amesbury, UK) was used to calculate the EV
size distribution after the ultracentrifugation.
4.14. Statistics
Data are expressed as the mean ± SD, and the statistical analysis was performed,
considering the groups compared were unpaired and using the nonparametric Kolmogorov–
Smirnov test with GraphPad Prism Version 9.0.1.
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5. Conclusions
In this study, we discovered that the modulation of the NF-kB pathway by the inhi-
bition of p65 using small inhibitors (JSH-23, MG-132 and curcumin) can prevent cellular
senescence and proinflammatory activation in MSCs and modulate the emerging SASP.
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Additionally, a small inhibitor treatment can prevent paracrine and proinflammatory
transmission by sEV.
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Appendix A
Table A1. List of drugs.
Drug Concentration Source Cat. No
Etoposide 1 µM MedChemExpress HY-13629
Palbociclib (CDK4/6i) 1 µM MedChemExpress HY-50767
TNF-A α 10 ng/mL ImmunoTools 11343013
JSH-23 10 µM MedChemExpress HY-13982
MG-132 10 µM MedChemExpress HY-13259
Curcumin 10 µM Sigma-Aldrich 458-37-7
Table A2. List of antibodies.
Antibody Dilution Source
CD90-FITC 1:100 BD Pharmigen
CD45-FITC 1:100 BD Pharmigen
CD73-PE 1:100 BD Pharmigen
CD105-FITC 1:100 BD Pharmigen
CD34-PE 1:100 BD Pharmigen
IgG1-PE 1:100 St. Cruz Biotechnology’s
IgG1-FITC 1:100 St. Cruz Biotechnology’s
Table A3. List of primers.
Target Species Forward Primer Reverse Primer
p65 Human ttcccgatctgagtccaggt gcttgtctcgggtttctgga
Nanog Human atgcctcacacggagactgt aagtgggttgtttgcctttg
Sox2 Human ctccgggacatgatcagc ggtagtgctgggacatgtgaa
Rex1 Human cgcaatcgcttgtcctcagagt gctctcaacgaacgctttccca
Oct4 Human ctcctggagggccaggaatc atatacacaggccgatgtgg
β-actin Human agagctacgagctgcctgac ggatgccacaggactcca
Int. J. Mol. Sci. 2021, 22, 3367 16 of 17
References
1. Fernández-Pernas, P.; Fafián-Labora, J.; Lesende-Rodriguez, I.; Mateos, J.; De la Fuente, A.; Fuentes, I.; Santos, J.D.T.; García, F.B.;
Arufe, M.C. 3,3′,5-triiodo-L-thyronine Increases In Vitro Chondrogenesis of Mesenchymal Stem Cells from Human Umbilical
Cord Stroma Through SRC2. J. Cell. Biochem. 2016, 117, 2097–2108. [CrossRef] [PubMed]
2. Fernandez-Pernas, P.; Rodríguez-Lesende, I.; De La Fuente, A.; Mateos, J.; Fuentes, I.; De Toro, J.; Blanco, F.J.; Arufe, M.C. CD105+
mesenchymal stem cells migrate into osteoarthritis joint: An animal model. PLoS ONE 2017, 12, e0188072. [CrossRef] [PubMed]
3. Fafián-Labora, J.A.; Fernández-Pernas, P.; Fuentes, I.; De Toro, J.; Oreiro, N.; Sangiao-Alvarellos, S.; Mateos, J.; Arufe, M.C.
Influence of age on rat bone-marrow mesenchymal stem cells potential. Sci. Rep. 2015, 5, 16765. [CrossRef] [PubMed]
4. Fafián-Labora, J.; Lesende-Rodriguez, I.; Fernández-Pernas, P.; Sangiao-Alvarellos, S.; Monserrat, L.; Arntz, O.J.; Van De
Loo, F.A.J.; Mateos, J.; Arufe, M.C. Effect of age on pro-inflammatory miRNAs contained in mesenchymal stem cell-derived
extracellular vesicles. Sci. Rep. 2017, 7, srep43923. [CrossRef] [PubMed]
5. Fafián-Labora, J.A.; Morente-López, M.; Arufe, M.C. Effect of aging on behaviour of mesenchymal stem cells. World J. Stem Cells
2019, 11, 337–346. [CrossRef]
6. Franceschi, C.; Garagnani, P.; Vitale, G.; Capri, M.; Salvioli, S. Inflammaging and ‘Garb-aging’. Trends Endocrinol. Metab. 2017, 28,
199–212. [CrossRef]
7. Ou, H.; Hoffmann, R.; González-López, C.; Doherty, G.J.; Korkola, J.E.; Muñoz-Espín, D. Cellular senescence in cancer: From
mechanisms to detection. Mol. Oncol. 2020. [CrossRef]
8. Wang, B.; Kohli, J.; Demaria, M. Senescent Cells in Cancer Therapy: Friends or Foes? Trends Cancer 2020, 6, 838–857. [CrossRef]
9. Fafián-Labora, J.A.; O’Loghlen, A. Classical and Nonclassical Intercellular Communication in Senescence and Ageing. Trends Cell
Biol. 2020, 30, 628–639. [CrossRef]
10. Borghesan, M.; Fafián-Labora, J.; Eleftheriadou, O.; Carpintero-Fernández, P.; Paez-Ribes, M.; Vizcay-Barrena, G.; Swisa, A.;
Kolodkin-Gal, D.; Ximénez-Embún, P.; Lowe, R.; et al. Small Extracellular Vesicles Are Key Regulators of Non-cell Autonomous
Intercellular Communication in Senescence via the Interferon Protein IFITM3. Cell Rep. 2019, 27, 3956–3971. [CrossRef]
11. Russell, A.E.; Sneider, A.; Witwer, K.W.; Bergese, P.; Bhattacharyya, S.N.; Cocks, A.; Cocucci, E.; Erdbrügger, U.; Falcon-Perez,
J.M.; Freeman, D.W.; et al. Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: An ISEV position paper
arising from the ISEV membranes and EVs workshop. J. Extracell. Vesicles 2019, 8, 1684862. [CrossRef]
12. Fafián-Labora, J.; Morente-López, M.; Sánchez-Dopico, M.J.; Arntz, O.J.; Van De Loo, F.A.J.; De Toro, J.; Arufe, M.C. Influence
of mesenchymal stem cell-derived extracellular vesicles in vitro and their role in ageing. Stem Cell Res. Ther. 2020, 11, 1–12.
[CrossRef]
13. Fafián-Labora, J.A.; Rodríguez-Navarro, J.A.; O’Loghlen, A. Small Extracellular Vesicles Have GST Activity and Ameliorate
Senescence-Related Tissue Damage. Cell Metab. 2020, 32, 71–86. [CrossRef]
14. Rodriguez-Navarro, J.A.; Pascual-Guerra, J.; Sacristan, S.; Nogales, M.D.C.; Fafián-Labora, J.A.; O’Loghlen, A. Extracellular
vesicles as potential tools for regenerative therapy. Mol. Cell. Oncol. 2020, 7. [CrossRef]
15. Gorlé, N.; Blaecher, C.; Bauwens, E.; Van den Driessche, C.; Balusu, S.; Vandewalle, J.; Van Cauwenberghe, C.; Van Wonterghem,
E.; Van Imschoot, G.; Liu, C.; et al. The choroid plexus epithelium as a novel player in the stomach-brain axis during Helicobacter
infection. Brain Behav. Immun. 2018, 69, 35–47. [CrossRef]
16. Lin, Y.-H.; Kang, L.; Feng, W.-H.; Cheng, T.-L.; Tsai, W.-C.; Huang, H.-T.; Lee, H.-C.; Chen, C.-H. Effects of Lipids and Lipoproteins
on Mesenchymal Stem Cells used in Cardiac Tissue Regeneration. Int. J. Mol. Sci. 2020, 21, 4770. [CrossRef]
17. Zhang, Q.; Lenardo, M.J.; Baltimore, D. 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell 2017, 168,
37–57. [CrossRef]
18. Liu, T.; Zhang, L.; Joo, D.; Sun, S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017, 2, 1–9. [CrossRef]
19. Taniguchi, K.; Karin, M. NF-κB, inflammation, immunity and cancer: Coming of age. Nat. Rev. Immunol. 2018, 18, 309–324.
[CrossRef]
20. Wang, J.; Jacob, N.K.; Ladner, K.J.; Beg, A.; Perko, J.D.; Tanner, S.M.; Liyanarachchi, S.; Fishel, R.; Guttridge, D.C. RelA/p65
functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep. 2009, 10, 1272–1278.
[CrossRef]
21. Böcker, W.; Docheva, D.; Prall, W.C.; Egea, V.; Pappou, E.; Rossmann, O.; Popov, C.; Mutschler, W.; Ries, C.; Schieker, M. IKK-2
is required for TNF-α-induced invasion and proliferation of human mesenchymal stem cells. J. Mol. Med. 2008, 86, 1183–1192.
[CrossRef] [PubMed]
22. Flores, R.R.; Clauson, C.L.; Cho, J.; Lee, B.-C.; McGowan, S.J.; Baker, D.J.; Niedernhofer, L.J.; Robbins, P.D. Expansion of myeloid-
derived suppressor cells with aging in the bone marrow of mice through a NF-κB-dependent mechanism. Aging Cell 2017, 16,
480–487. [CrossRef] [PubMed]
23. Huang, M.-C.; Liao, J.-J.; Bonasera, S.; Longo, D.L.; Goetzl, E.J. Nuclear factor-κB-dependent reversal of aging-induced alterations
in T cell cytokines. FASEB J. 2008, 22, 2142–2150. [CrossRef] [PubMed]
24. Valenzuela, C.A.; Quintanilla, R.; Olate-Briones, A.; Venturini, W.; Mancilla, D.; Cayo, A.; Moore-Carrasco, R.; Brown, N.E.
SASP-Dependent Interactions between Senescent Cells and Platelets Modulate Migration and Invasion of Cancer Cells. Int. J.
Mol. Sci. 2019, 20, 5292. [CrossRef]
25. Chen, X.; Liu, G.; Yuan, Y.; Wu, G.; Wang, S.; Yuan, L. NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory
bowel disease via NF-κB signaling. Cell Death Dis. 2019, 10, 1–12. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 3367 17 of 17
26. Qiu, B.; Xu, X.; Yi, P.; Hao, Y. Curcumin reinforces MSC-derived exosomes in attenuating osteoarthritis via modulating the
miR-124/NF-kB and miR-143/ROCK1/TLR9 signalling pathways. J. Cell. Mol. Med. 2020, 24, 10855–10865. [CrossRef]
27. Nakajima, S.; Kato, H.; Takahashi, S.; Johno, H.; Kitamura, M. Inhibition of NF-κB by MG132 through ER stress-mediated
induction of LAP and LIP. FEBS Lett. 2011, 585, 2249–2254. [CrossRef]
28. Van Deursen, J.M. The role of senescent cells in ageing. Nat. Cell Biol. 2014, 509, 439–446. [CrossRef]
29. Cao, X.; Lin, W.; Liang, C.; Zhang, D.; Yang, F.; Zhang, Y.; Zhang, X.; Feng, J.; Chen, C. Naringin rescued the TNF-α-induced
inhibition of osteogenesis of bone marrow-derived mesenchymal stem cells by depressing the activation of NF-κB signaling
pathway. Immunol. Res. 2015, 62, 357–367. [CrossRef]
30. Liu, T.; Long, T.; Li, H. Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein
1/nuclear factor-κB-dependent pathway. Exp. Ther. Med. 2021, 21, 1. [CrossRef]
31. Pandey, A.C.A.; Semon, J.; Kaushal, D.; O’Sullivan, R.P.; Glowacki, J.; Gimble, J.M.A.; Bunnell, B. MicroRNA profiling reveals age-
dependent differential expression of nuclear factor κB and mitogen-activated protein kinase in adipose and bone marrow-derived
human mesenchymal stem cells. Stem Cell Res. Ther. 2011, 2, 49. [CrossRef]
32. Wyld, L.; Bellantuono, I.; Tchkonia, T.; Morgan, J.; Turner, O.; Foss, F.; George, J.; Danson, S.; Kirkland, J.L. Senescence and Cancer:
A Review of Clinical Implications of Senescence and Senotherapies. Cancers 2020, 12, 2134. [CrossRef]
33. Chien, Y.; Scuoppo, C.; Wang, X.; Fang, X.; Balgley, B.; Bolden, J.E.; Premsrirut, P.; Luo, W.; Chicas, A.; Lee, C.S.; et al. Control of
the senescence-associated secretory phenotype by NF-B promotes senescence and enhances chemosensitivity. Genes Dev. 2011, 25,
2125–2136. [CrossRef]
34. Worthington, E.N.; Hagood, J.S. Therapeutic use of Extracellular Vesicles for Acute and Chronic Lung Disease. Int. J. Mol. Sci.
2020, 21, 2318. [CrossRef]
35. Van Esch, B.C.A.M.; Porbahaie, M.; Abbring, S.; Garssen, J.; Potaczek, D.P.; Savelkoul, H.F.J.; Neerven, R.J.J. The Impact of Milk
and its Components on Epigenetic Programming of Immune Function in Early Life and Beyond: Implications for Allergy and
Asthma. Front. Immunol. 2020, 11, 2141. [CrossRef]
36. Alhamwe, B.A.; Miethe, S.; Von Strandmann, E.P.; Potaczek, D.P.; Garn, H. Epigenetic Regulation of Airway Epithelium Immune
Functions in Asthma. Front. Immunol. 2020, 11. [CrossRef]
37. Deng, W.; Tang, T.; Hou, Y.; Zeng, Q.; Wang, Y.; Fan, W.; Qu, S. Extracellular vesicles in atherosclerosis. Clin. Chim. Acta 2019, 495,
109–117. [CrossRef]
38. Cavallo, C.; Merli, G.; Borzì, R.M.; Zini, N.; D’Adamo, S.; Guescini, M.; Grigolo, B.; Di Martino, A.; Santi, S.; Filardo, G. Small Extra-
cellular Vesicles from adipose derived stromal cells significantly attenuate in vitro the NF-κB dependent inflammatory/catabolic
environment of osteoarthritis. Sci. Rep. 2021, 11, 1–16. [CrossRef]
